Lactobacillus rhamnosus LRa05 Ameliorate Hyperglycemia through a Regulating Glucagon-Mediated Signaling Pathway and Gut Microbiota in Type 2 Diabetic Mice

Introduction

Currently, T2DM is a severe disease worldwide and is seriously threatening human health and well-being. Clinical research and animal studies have suggested that rational intake of probiotics could treat and alleviate diabetes. This study aimed to investigate the hypoglycemic activity of the Lactobacillus rhamnosus LRa05, and provide key insights for L.rhamnosus LRa05 to alleviate hyperglycemia via the gut microbiota−liver axis.

Study Design

Conclusion

LRa05 attenuated insulin resistance, hepatic oxidative stress, and inflammation, reshaped gut microbiota, resulting in increased beneficial bacteria and decreased potential pathogenic bacteria. Thus, LRa05 may be used as a functional food supplement for modulating the disorder glucose metabolism and gut microbiota in T2DM.

Main Results

① Fasting blood glucose, glucose tolerance

② Pancreatic, liver

③ Insulin resistance

④ Hepatic oxidative stress

⑤ Inflammation

⑥ Gut microbiota